The impact of making vaccines thermostable in Niger's vaccine supply chain
- 10 July 2012
- Vol. 30 (38) , 5637-5643
- https://doi.org/10.1016/j.vaccine.2012.06.087
Abstract
No abstract availableKeywords
Funding Information
- National Institute of General Medical Sciences Models of Infectious Disease Agent Study (1U54GM088491-0109)
This publication has 18 references indexed in Scilit:
- The optimal number of routine vaccines to order at health clinics in low or middle income countriesVaccine, 2011
- Evaluation of an outside-the-Cold-Chain Vaccine Delivery Strategy in Remote Regions of Western ChinaPublic Health Reports®, 2009
- Characterization of a thermostable hepatitis B vaccine formulationVaccine, 2009
- Opportunities and challenges of developing thermostable vaccinesExpert Review of Vaccines, 2009
- Editorial Commentary:Digital Decision Making: Computer Models and Antibiotic Prescribing in the Twenty‐First CenturyClinical Infectious Diseases, 2008
- Immunogenicity and safety of aerosolized measles vaccine: Systematic review and meta-analysisVaccine, 2008
- An economic evaluation of thermostable vaccines in Cambodia, Ghana and BangladeshVaccine, 2007
- Freezing temperatures in the vaccine cold chain: A systematic literature reviewVaccine, 2007
- Screening the United States Blood Supply for West Nile Virus: A Question of Blood, Dollars, and SensePLoS Medicine, 2006
- Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions.2004